Skip to main content

Table 4 Changes of serum markers in leucine enriched and standard BCAA dietary supplements

From: Quick and effective improvement of leucine enriched dietary supplement on malnutrition in acute stroke patients receiving enteral tube feeding

Case

TTR on admission

TTR on the fifth day

TTR on the seventh day

Alb on admission

Alb on the fifth day

Alb on the seventh day

CRP on admission

CRP on the fifth day

CRP on the seventh day

Cre on admission

Cre on the fifth day

Cre on the seventh day

Leucine enriched BCAA dietary supplement

 1

13.1

14.0

23.1

4.0

2.9

3.2

8.831

3.038

1.183

0.73

0.53

0.52

 2

16.1

10.8

15.7

4.3

3.1

2.6

0.870

16.376

6.161

0.78

1.25

1.16

 3

12.0

7.3

11.3

3.0

2.3

2.5

1.862

10.404

4.774

6.96

5.67

5.79

 4

12.3

3.5

4.4

4.1

2.2

2.0

0.324

38.079

21.280

1.04

3.97

2.03

 5

12.7

12.4

13.3

2.8

2.1

2.1

1.020

2.160

0.941

1.75

2.06

1.83

 6

9.0

7.3

10.2

3.0

2.6

2.4

3.705

5.431

2.131

0.74

0.74

0.79

 7

17.2

12.4

20.5

3.5

2.6

2.7

0.036

2.009

0.385

0.71

0.69

0.62

 8

7.9

6.7

8.2

3.4

2.5

2.6

8.168

24.719

15.136

0.68

0.92

2.09

 9

8.2

8.4

17.2

3.2

2.4

2.6

1.673

8.285

1.457

0.86

0.70

0.65

 10

24.7

11.9

10.9

4.2

2.7

2.1

0.016

6.469

5.849

0.92

1.01

0.82

 11

16.9

13.3

20.2

4.1

3.1

3.0

0.273

5.243

4.605

9.35

4.74

5.34

 12

23.3

12.7

19.6

4.2

2.8

2.9

0.093

4.078

1.045

0.59

0.54

0.63

 13

12.5

12.6

20.4

3.3

3.0

3.4

9.265

5.199

8.887

0.76

0.56

0.64

 14

17.8

11.8

15.9

2.9

2.4

2.5

1.212

4.066

6.563

0.70

0.65

0.50

 15

12.2

10.7

8.1

3.7

3.4

2.9

0.115

0.598

6.046

0.83

0.70

0.64

Median

12.9

11.9

15.8

3.5

2.6

2.6

1.116

5.337

4.690

0.77

0.83

0.81

MDB A-5

 

−3.6 (p < 0.001)

  

−0.9 (p < 0.0001)

  

4.0 (p < 0.01)

  

−0.05 (ns)

 

MDB 5–7

  

4.1 (p < 0.001)

  

0.1 (ns)

  

−1.9 (p < 0.05)

  

−0.05 (ns)

Standard BCAA dietary supplement

 1

11.8

11.0

10.4

4.0

2.6

2.4

1.332

5.301

3.268

0.77

0.72

0.70

 2

8.1

10.4

11.1

2.9

2.3

2.2

3.796

0.555

0.791

0.49

0.54

0.65

 3

8.3

8.3

12.1

3.0

2.5

2.7

0.822

5.924

1.721

0.65

0.51

0.51

 4

8.0

9.5

10.1

3.0

2.0

2.1

3.388

4.058

2.419

1.15

1.10

1.08

 5

10.4

8.4

8.9

3.7

2.6

2.7

0.407

3.396

2.499

0.9

0.85

0.87

 6

20.3

13.2

13.6

3.7

3.3

3.1

0.050

0.149

0.210

0.68

0.63

0.64

 7

17.1

13.6

12.0

3.5

2.9

2.7

0.028

4.327

5.864

0.71

0.62

0.60

 8

5.8

6.2

6.6

2.8

2.3

2.3

8.327

4.095

5.587

0.47

0.41

0.42

 9

12.8

12.8

12.0

4.4

3.5

3.4

0.524

0.748

0.984

0.48

0.45

0.40

 10

10.6

9.8

10.9

2.9

2.3

2.2

2.345

7.703

3.041

0.60

0.40

0.39

 11

10.7

3.1

4.1

3.2

1.5

1.5

0.172

23.428

18.559

1.68

1.61

1.85

 12

12.4

11.6

12.0

3.4

3.0

2.9

0.227

0.227

0.964

0.72

0.64

0.57

 13

8.8

8.8

10.5

3.0

2.6

2.6

0.015

0.812

0.196

0.52

0.52

0.48

 14

13.5

6.4

4.1

3.5

2.5

2.2

2.819

30.905

33.414

0.92

0.97

0.85

Median

10.7

9.7

10.7

3.3

2.6

2.5

0.673

4.077

2.459

0.70

0.63

0.62

MDB A-5

 

−0.8 (< 0.05)

  

−0.6 (p < 0.0001)

  

1.893 (p < 0.05)

  

−0.015 (p < 0.01)

 

MDB 5–7

  

0.45 (ns)

  

−0.1 (ns)

  

−0.278 (ns)

  

− 0.05 (ns)

  1. BCAA branched-chain amino acids, TTR transthretin (mg/dl), Alb albumin (g/dl), CRP high-sensitivity C-reactive protein (mg/dl), Cre creatinine (mg/dl), MDB A-5 median difference between on admission and the fifth day, MDB 5–7 median difference between on the fifth and the seventh day, p probability, ns not significant
Back to article page

BMC Emergency Medicine

ISSN: 1471-227X

Contact us